title: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
authors.forename: Craig T
authors.initials: CT
authors.lastname: January
authors.forename: L Samuel
authors.initials: LS
authors.lastname: Wann
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Alpert
authors.forename: Hugh
authors.initials: H
authors.lastname: Calkins
authors.forename: Joaquin E
authors.initials: JE
authors.lastname: Cigarroa
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Cleveland
authors.forename: Jamie B
authors.initials: JB
authors.lastname: Conti
authors.forename: Patrick T
authors.initials: PT
authors.lastname: Ellinor
authors.forename: Michael D
authors.initials: MD
authors.lastname: Ezekowitz
authors.forename: Michael E
authors.initials: ME
authors.lastname: Field
authors.forename: Katherine T
authors.initials: KT
authors.lastname: Murray
authors.forename: Ralph L
authors.initials: RL
authors.lastname: Sacco
authors.forename: William G
authors.initials: WG
authors.lastname: Stevenson
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Tchou
authors.forename: Cynthia M
authors.initials: CM
authors.lastname: Tracy
authors.forename: Clyde W
authors.initials: CW
authors.lastname: Yancy
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000503:physiopathology; D001281:Atrial Fibrillation / Q000145:classification / Q000503:physiopathology / Q000628:therapy*; D001341:Autonomic Nervous System / Q000503:physiopathology; D002097:C-Reactive Protein / Q000032:analysis; D002303:Cardiac Output, Low / Q000503:physiopathology; D017115:Catheter Ablation; D015897:Comorbidity; D017147:Defibrillators, Implantable; D017548:Echocardiography, Transesophageal; D004554:Electric Countershock; D004562:Electrocardiography; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006325:Heart Atria / Q000002:abnormalities / Q000503:physiopathology / Q000601:surgery; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D020097:Natriuretic Peptide, Brain / Q000097:blood; D018384:Oxidative Stress / Q000502:physiology; D010138:Pacemaker, Artificial; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000502:physiology; D018570:Risk Assessment; D012307:Risk Factors; D055989:Septal Occluder Device; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013923:Thromboembolism / Q000503:physiopathology / Q000517:prevention & control; D020257:Ventricular Remodeling / Q000502:physiology
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D020097:Natriuretic Peptide, Brain; D002097:C-Reactive Protein
keywords: AHA Scientific Statements; atrial fibrillation; cardio-renal physiology/pathophysiology; cardiovascular surgery: transplantation, ventricular assistance, cardiomyopathy; epidemiology; full revision; health policy and outcome research; other atrial fibrillation